JP2020533016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533016A5 JP2020533016A5 JP2020529100A JP2020529100A JP2020533016A5 JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5 JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antigen
- acid sequence
- seq
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023105890A JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539970P | 2017-08-01 | 2017-08-01 | |
| US62/539,970 | 2017-08-01 | ||
| US201862654112P | 2018-04-06 | 2018-04-06 | |
| US62/654,112 | 2018-04-06 | ||
| PCT/US2018/044778 WO2019028125A1 (en) | 2017-08-01 | 2018-08-01 | BISPECIFIC ANTIBODIES AND USES THEREOF |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105890A Division JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Division JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533016A JP2020533016A (ja) | 2020-11-19 |
| JP2020533016A5 true JP2020533016A5 (enExample) | 2021-09-09 |
| JP7801095B2 JP7801095B2 (ja) | 2026-01-16 |
Family
ID=65233048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529100A Active JP7801095B2 (ja) | 2017-08-01 | 2018-08-01 | 二重特異性抗体およびその使用 |
| JP2023105890A Active JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Pending JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105890A Active JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Pending JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US12049517B2 (enExample) |
| EP (2) | EP4088783A1 (enExample) |
| JP (3) | JP7801095B2 (enExample) |
| KR (2) | KR102794369B1 (enExample) |
| CN (3) | CN111356477B (enExample) |
| ES (1) | ES3023158T3 (enExample) |
| WO (1) | WO2019028125A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7801095B2 (ja) * | 2017-08-01 | 2026-01-16 | エイビー セラピューティクス インコーポレイテッド | 二重特異性抗体およびその使用 |
| CN113660956B (zh) * | 2019-01-28 | 2024-10-29 | Ab诊疗公司 | 双特异性抗体及其用途 |
| CN113677705A (zh) * | 2019-03-04 | 2021-11-19 | 南通壹宸生物医药科技有限公司 | 新型双特异性结合分子及其药物偶联物 |
| JP2022525275A (ja) * | 2019-03-28 | 2022-05-12 | エービー ストゥーディオ インコーポレイテッド | ヘテロ多量体タンパク質及びその使用法 |
| JP7369297B2 (ja) * | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| EP4253415A4 (en) * | 2020-11-12 | 2024-10-02 | Mabwell (Shanghai) Bioscience Co., Ltd. | Antibody and preparation method therefor |
| CN112430271B (zh) * | 2020-11-13 | 2021-09-03 | 武汉滨会生物科技股份有限公司 | 一种双特异性单链抗体及应用 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| CN116143948A (zh) * | 2023-02-14 | 2023-05-23 | 中国药科大学 | 一种以Jurkat为平台的靶向CD24和PD-L1双特异性嵌合抗原受体CAR及其应用 |
| WO2024255756A1 (zh) * | 2023-06-13 | 2024-12-19 | 南京维立志博生物科技股份有限公司 | 基于共同轻链产生双特异性抗体的方法 |
| WO2026011331A1 (zh) * | 2024-07-10 | 2026-01-15 | 嘉和生物药业有限公司 | 一种稳定的双特异性抗体组合物 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| AU2003295330A1 (en) | 2002-09-16 | 2004-05-04 | Elusys Therapeutics, Inc. | Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| US8337841B2 (en) | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| NZ569204A (en) | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
| JP5144499B2 (ja) * | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| JP2009544761A (ja) * | 2006-06-14 | 2009-12-17 | マクロジェニクス，インコーポレーテッド | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| EP3553089A1 (en) * | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| IL282953B2 (en) | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| BR112016000666A2 (pt) * | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| JP6510532B2 (ja) | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| WO2016077505A2 (en) | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| JP6696982B2 (ja) * | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| CN110658340B (zh) | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| JP2018502859A (ja) | 2015-01-09 | 2018-02-01 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 二重特異性抗体を用いた事前標的指向化による腫瘍の治療 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2017010874A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
| PL3368572T5 (pl) | 2015-10-02 | 2026-07-20 | Les Laboratoires Servier | Przeciwciała anty-PD-1 oraz kompozycje |
| EP3387013B1 (en) * | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| JP7801095B2 (ja) * | 2017-08-01 | 2026-01-16 | エイビー セラピューティクス インコーポレイテッド | 二重特異性抗体およびその使用 |
-
2018
- 2018-08-01 JP JP2020529100A patent/JP7801095B2/ja active Active
- 2018-08-01 CN CN201880062833.7A patent/CN111356477B/zh active Active
- 2018-08-01 ES ES18840836T patent/ES3023158T3/es active Active
- 2018-08-01 EP EP22160823.5A patent/EP4088783A1/en active Pending
- 2018-08-01 KR KR1020207006195A patent/KR102794369B1/ko active Active
- 2018-08-01 US US16/635,878 patent/US12049517B2/en active Active
- 2018-08-01 CN CN202111079150.2A patent/CN113896797B/zh active Active
- 2018-08-01 WO PCT/US2018/044778 patent/WO2019028125A1/en not_active Ceased
- 2018-08-01 CN CN202411097878.1A patent/CN119019564A/zh active Pending
- 2018-08-01 EP EP18840836.3A patent/EP3661555B1/en active Active
- 2018-08-01 KR KR1020257011307A patent/KR20250052490A/ko active Pending
-
2021
- 2021-08-10 US US17/398,853 patent/US11440972B2/en active Active
- 2021-08-10 US US17/398,807 patent/US11566083B2/en active Active
-
2023
- 2023-06-28 JP JP2023105890A patent/JP7685771B2/ja active Active
-
2024
- 2024-06-14 US US18/743,295 patent/US20240336702A1/en not_active Abandoned
-
2025
- 2025-04-25 JP JP2025072790A patent/JP2025111661A/ja active Pending
- 2025-08-20 US US19/304,720 patent/US20260085131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527553A5 (enExample) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2025160458A5 (enExample) | ||
| JP2023504016A5 (enExample) | ||
| JP2024522360A5 (enExample) | ||
| JP2019532619A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2020536504A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| JP2018532766A5 (enExample) | ||
| JP2021515798A5 (enExample) | ||
| JP2023551027A5 (enExample) | ||
| JP2021516051A5 (enExample) | ||
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| JP2020534830A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2021520832A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2018505681A5 (enExample) | ||
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2021517152A5 (enExample) | ||
| JP2023509390A5 (enExample) | ||
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use |